Alpha Cognition Inc. ACOG
for patients suffering from neurodegenerative diseases, such as Alzheimer's disease ("AD"), for which there are limited
or no treatment options. We focus on the development of commercial manufacturing and commercial sales of ZUNVEYL oral tablet formulation.
Our commercial development program for ZUNVEYL is primarily focused on building a long-term care ("LTC") commercial team that
can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors ("AChEI")
Valuation FY2025 figures against the last close
Where the revenue comes from as reported in the latest 10-K
Revenue by geography
- United States
- Canada
| Region | FY2025 |
|---|---|
| United States | $6.8M |
| Canada | $3.4M |
As the company reported it, from the “Segment Information - Schedule of Currently Operates in a Single Reportable Operating Segment (Details)” note of its latest 10-K. Every figure here has been checked against the total revenue the same filing reported. Regions are the filer's own and are not mapped onto a standard list — one company's “Americas” and another's “United States” are different areas, and making them look comparable would mean making at least one of them wrong. Slices under 1% are folded into “Other”.
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | $10.2M | — | — | — |
| Cost of revenue | $603.4K | — | — | — |
| Gross profit | $9.6M | — | — | — |
| R&D | $1.9M | $3.9M | $4.9M | — |
| SG&A | $29.1M | $8.0M | $5.1M | — |
| Total operating expenses | $32.9M | $12.0M | $9.9M | — |
| Operating income | -$22.7M | -$12.0M | -$9.9M | — |
| Interest expense | — | $105.3K | $17.5K | — |
| Net income | -$20.7M | -$14.8M | -$13.8M | — |
| EPS, basic | -1.17 | -2.04 | -3.84 | — |
| EPS, diluted | -1.18 | -2.04 | -3.84 | — |
| Shares, diluted (wtd. avg.) | 17.7M | 7.2M | 3.6M | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Cash and equivalents | $66.0M | $48.5M | $1.5M | $2.1M |
| Receivables | $4.2M | — | — | — |
| Inventory | $5.1M | $615.1K | — | — |
| Total current assets | $79.0M | $50.3M | $1.9M | — |
| Property, plant and equipment | $328.5K | $27.1K | $1.7K | — |
| Other intangibles | $391.4K | $413.0K | $532.0K | — |
| Total assets | $79.7M | $50.7M | $2.5M | — |
| Accounts payable | $3.1M | $872.7K | $475.6K | — |
| Total current liabilities | $9.1M | $3.4M | $2.6M | — |
| Total liabilities | $17.2M | $11.6M | $7.2M | — |
| Retained earnings | -$97.1M | -$76.4M | -$61.6M | — |
| Total equity | $62.5M | $39.1M | -$4.7M | -$1.3M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Operating cash flow | -$20.4M | -$7.8M | -$8.8M | — |
| Depreciation and amortisation | — | $1.3K | $2.1K | — |
| Stock-based compensation | $4.9M | $1.1M | $2.4M | — |
| Capital expenditure | $293.5K | $26.7K | — | — |
| Investing cash flow | -$293.5K | -$26.7K | — | — |
| Financing cash flow | $38.2M | $54.9M | $8.2M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001213900-26-037614.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Revenue | — | — | — | $10.2M |
| Gross profit | — | — | — | $9.6M |
| Net income | — | -$13.8M | -$14.8M | -$20.7M |
Recent filings and events
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Officer or director change Item 5.02
- Officer or director change Item 5.02
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Officer or director change Item 5.02
- Officer or director change Item 5.02
- Auditor changed The company changed auditors. Sometimes routine; historically one of the more reliable warnings that something is wrong. Item 4.01
- Auditor changed Item 4.01
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2836
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AMGN | AMGEN INC | $237.48B | 30.9x | 10.0% |
| GILD | GILEAD SCIENCES, INC. | $193.48B | 23.0x | 2.4% |
| MRNA | Moderna, Inc. | $79.89B | — | -39.9% |
| RVMD | Revolution Medicines, Inc. | $40.08B | — | — |
| BIIB | BIOGEN INC. | $37.01B | 28.5x | 2.2% |
| EXEL | EXELIXIS, INC. | $15.99B | 23.2x | 7.0% |
| NBIX | NEUROCRINE BIOSCIENCES INC | $14.51B | 30.6x | 21.4% |
| HALO | HALOZYME THERAPEUTICS, INC. | $14.26B | 49.1x | 37.6% |